1. Pasireotide achieves biochemical control in some acromegaly patients who fail first-generation somatostatin receptor analogs (SSAs), yet it also causes far more hyperglycemia than those agents. A clinician notes that both properties trace to the same receptor feature. Which single pharmacological property of pasireotide best explains both its enhanced efficacy in refractory acromegaly and its high hyperglycemia risk?
A) Its rapid hepatic metabolism, which produces an active metabolite responsible for added GH (growth hormone) suppression while the parent drug independently impairs insulin secretion
B) Its high affinity for SSTR5 (somatostatin receptor subtype 5), which adds GH suppression beyond SSTR2-selective agents at the pituitary while simultaneously suppressing insulin and incretin secretion at pancreatic and intestinal cells
C) Its selective antagonism of the GH receptor at the liver, which lowers IGF-1 (insulin-like growth factor-1) while also blocking hepatic insulin signaling
D) Its long depot half-life, which sustains pituitary GH suppression and coincidentally prolongs exposure of the gallbladder to cholecystokinin (CCK) suppression
E) Its agonism at the ghrelin receptor (GHSR-1a), which augments GH suppression while stimulating appetite and weight gain that drives hyperglycemia
ANSWER: B
Rationale:
Pasireotide's defining pharmacological feature is its high affinity for SSTR5 (somatostatin receptor subtype 5) — roughly 40-fold greater than octreotide — together with broad pan-SSTR binding (SSTR1, SSTR2, SSTR3, SSTR5). This single property explains both observations. At the pituitary somatotroph, the added SSTR5 (and SSTR1) activity provides GH suppression beyond what SSTR2-selective agents achieve, which is why pasireotide controls some refractory patients. At pancreatic beta cells and intestinal endocrine cells, that same high SSTR5 activity profoundly suppresses insulin secretion and incretin (GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)) release, producing the high rate of hyperglycemia (roughly 57 to 73%). One receptor property, two clinical consequences.
Option A: Option A is incorrect because pasireotide's efficacy and hyperglycemia are not explained by an active hepatic metabolite; the unifying basis is receptor binding (SSTR5), not metabolism.
Option C: Option C is incorrect because pasireotide is a somatostatin receptor agonist acting at the pituitary and pancreas, not a GH receptor antagonist at the liver; that mechanism describes pegvisomant and does not account for hyperglycemia through insulin signaling blockade.
Option D: Option D is incorrect because depot half-life governs dosing interval, not the dual efficacy-plus-hyperglycemia profile; CCK suppression relates to gallstones, not to GH suppression or hyperglycemia.
Option E: Option E is incorrect because pasireotide is a somatostatin receptor agonist, not a ghrelin receptor (GHSR-1a) agonist; it suppresses rather than augments the GH axis, and its hyperglycemia arises from insulin/incretin suppression, not appetite-driven weight gain.
2. A patient on pasireotide develops hyperglycemia. The team must choose an antidiabetic strategy. They reason through why the receptor-level cause of the hyperglycemia makes some drug classes effective and others nearly useless. Which choice correctly integrates the mechanism of pasireotide hyperglycemia with the expected efficacy of antidiabetic classes?
A) Metformin and SGLT2 (sodium-glucose cotransporter-2) inhibitors are first-line because pasireotide hyperglycemia is driven by insulin resistance and renal glucose reabsorption, both of which these agents directly correct
B) DPP-4 (dipeptidyl peptidase-4) inhibitors are first-line because pasireotide raises endogenous incretin levels, and preventing their degradation amplifies an already-elevated incretin signal
C) Sulfonylureas are first-line because pasireotide hyperglycemia results purely from beta-cell destruction, and forcing residual beta cells to secrete insulin is the only effective approach
D) GLP-1 (glucagon-like peptide-1) receptor agonists and insulin are preferred because pasireotide suppresses insulin and incretin secretion at the source; agents that bypass the suppressed endogenous pathway (a GLP-1 receptor agonist acting directly on the receptor, or exogenous insulin) restore the secretory drive, whereas DPP-4 inhibitors are ineffective because there is little endogenous incretin left to preserve
E) No pharmacologic therapy is effective for pasireotide hyperglycemia; only discontinuation of pasireotide will lower glucose, so antidiabetic drug selection is irrelevant
ANSWER: D
Rationale:
Pasireotide hyperglycemia is driven principally by suppression of insulin secretion and of incretin (GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)) release at the source, through high-affinity SSTR5 activity at pancreatic and intestinal endocrine cells. Integrating that mechanism with drug-class action explains the correct strategy: GLP-1 receptor agonists act directly on the GLP-1 receptor, bypassing the suppressed endogenous incretin pathway, and insulin directly replaces the suppressed secretory drive — both restore effective insulin action. DPP-4 inhibitors, which work by preventing degradation of endogenous incretins, have little substrate to preserve because incretin secretion is suppressed upstream, so they are largely ineffective.
Option A: Option A is incorrect because pasireotide hyperglycemia is predominantly a secretory defect (reduced insulin secretion), not primarily insulin resistance; metformin and SGLT2 inhibitors do not address the secretory deficit and underperform.
Option B: Option B is incorrect because pasireotide lowers, not raises, endogenous incretin levels; DPP-4 inhibitors therefore have minimal effect, the opposite of the option's premise.
Option C: Option C is incorrect because pasireotide causes reversible functional suppression of insulin secretion, not beta-cell destruction; sulfonylureas depend on a secretory pathway that is pharmacologically suppressed and are not the preferred choice.
Option E: Option E is incorrect because effective pharmacologic options do exist (GLP-1 receptor agonists and insulin); pasireotide hyperglycemia is manageable without necessarily discontinuing the drug, so drug selection is far from irrelevant.
3. A resident is puzzled that during effective pegvisomant therapy serum IGF-1 (insulin-like growth factor-1) falls while serum GH (growth hormone) simultaneously rises. Integrating pegvisomant's site of action with the physiology of the GH–IGF-1 feedback loop, which explanation correctly accounts for this divergence?
A) Pegvisomant blocks the GH receptor at peripheral tissues (notably the liver), reducing IGF-1 generation; because IGF-1 normally exerts negative feedback that restrains pituitary GH secretion, the fall in IGF-1 disinhibits the somatotroph, so pituitary GH output rises even as IGF-1 declines
B) Pegvisomant stimulates hepatic IGF-1 clearance while simultaneously stimulating pituitary GH synthesis, so the two markers move independently for unrelated reasons
C) Pegvisomant suppresses pituitary GH secretion, and the rise in measured GH reflects assay cross-reactivity with the drug itself rather than a true increase in secreted GH
D) Pegvisomant increases IGF-binding protein levels so that total IGF-1 falls while free IGF-1 and GH both rise, with no involvement of feedback
E) Pegvisomant agonizes the GH receptor more potently than native GH, raising IGF-1 transiently before a compensatory fall, while GH rises from direct pituitary stimulation
ANSWER: A
Rationale:
The divergence is explained by integrating pegvisomant's peripheral site of action with the long-loop GH–IGF-1 feedback system. Pegvisomant is a GH receptor antagonist that blocks GH action at peripheral target tissues, principally the liver, reducing IGF-1 generation; this is why serum IGF-1 falls and is the marker of effective therapy. Separately, IGF-1 normally provides negative feedback to the pituitary (and hypothalamus) to restrain GH secretion. When pegvisomant lowers IGF-1, that feedback brake is released, the somatotroph is disinhibited, and pituitary GH secretion rises. Thus IGF-1 falls (drug effect at the receptor) while GH rises (loss of feedback) — the same intervention drives both, in opposite directions.
Option B: Option B is incorrect because the two markers do not move for unrelated reasons; they are linked through the feedback loop, with the IGF-1 fall causing the GH rise.
Option C: Option C is incorrect because pegvisomant does not suppress pituitary GH secretion, and the GH rise is a genuine secretory increase, not an assay artifact.
Option D: Option D is incorrect because the divergence is not explained by binding-protein shifts; the mechanism is GH receptor blockade lowering IGF-1 and the resulting loss of negative feedback raising GH.
Option E: Option E is incorrect because pegvisomant is an antagonist, not a more potent agonist, at the GH receptor; it does not raise IGF-1, and GH rises from loss of feedback, not direct pituitary stimulation.
4. A patient with acromegaly has residual disease after surgery and a pituitary tumor abutting the optic chiasm with early visual field changes. Medical therapy is needed both to control IGF-1 (insulin-like growth factor-1) and to address tumor mass. Integrating each drug's mechanism with its effect on tumor volume, which choice is best and why?
A) Pegvisomant monotherapy, because as a GH (growth hormone) receptor antagonist it normalizes IGF-1 in the highest proportion of patients and therefore also produces the greatest tumor shrinkage
B) Pegvisomant monotherapy, because removing IGF-1 negative feedback shrinks the somatotroph adenoma directly through reduced pituitary stimulation
C) A somatostatin receptor analog (SSA) such as octreotide or lanreotide, because SSAs act at the pituitary somatotroph and can produce tumor shrinkage in a meaningful proportion of patients, addressing the mass effect on the optic chiasm, whereas pegvisomant does not reduce tumor volume
D) Macimorelin, because as a ghrelin receptor agonist it both lowers IGF-1 and reliably reduces tumor size
E) Sermorelin, because stimulating endogenous GH release downregulates the tumor through negative feedback and relieves chiasmal compression
ANSWER: C
Rationale:
This requires integrating mechanism with tumor-volume effect. The clinical priority is a drug that both lowers IGF-1 and can reduce tumor mass threatening the optic chiasm. Somatostatin receptor analogs (SSAs) act directly at the pituitary somatotroph and can produce clinically meaningful tumor shrinkage in a substantial proportion of patients, making an SSA the appropriate choice when mass effect must be addressed medically. Pegvisomant, although highly effective at normalizing IGF-1, acts only peripherally at the GH receptor and does not reduce pituitary tumor volume — so it does not relieve chiasmal compression.
Option A: Option A is incorrect because pegvisomant's high rate of IGF-1 normalization does not translate into tumor shrinkage; it has no tumor-volume effect, so the inference is wrong.
Option B: Option B is incorrect because pegvisomant does not shrink the adenoma; in fact it raises GH and is monitored with periodic imaging precisely because it does not prevent tumor growth.
Option D: Option D is incorrect because macimorelin is an oral diagnostic ghrelin receptor agonist, not a therapy for acromegaly; it would stimulate, not suppress, the GH axis and does not reduce tumor size.
Option E: Option E is incorrect because sermorelin is a GHRH analog that stimulates GH release and is not a treatment for acromegaly; stimulating the axis would be counterproductive and does not relieve chiasmal compression.
5. Two patients have growth hormone (GH) deficiency. Patient 1 has partial hypothalamic GH deficiency with an intact pituitary. Patient 2 has had the pituitary somatotroph population destroyed by prior radiation. A GHRH (growth hormone-releasing hormone) analog such as sermorelin is being considered. Applying the mechanism of GHRH analogs to these two situations, what should the clinician expect?
A) The GHRH analog will work equally well in both patients because it directly replaces growth hormone in the circulation regardless of pituitary status
B) The GHRH analog will work in Patient 2 but not Patient 1, because radiation sensitizes the remaining tissue to GHRH stimulation
C) The GHRH analog will fail in both patients because GHRH analogs cannot stimulate GH release under any circumstances
D) The GHRH analog will work only if combined with a somatostatin receptor analog in both patients, irrespective of somatotroph status
E) The GHRH analog can stimulate GH release in Patient 1, who retains an intact somatotroph pool, but will be ineffective in Patient 2, because GHRH analogs act upstream at the pituitary and require functioning somatotrophs to release endogenous GH
ANSWER: E
Rationale:
GHRH analogs such as sermorelin act upstream, stimulating pituitary somatotrophs to release endogenous GH; they do not replace GH directly. Applying this mechanism: Patient 1, with partial hypothalamic deficiency but an intact pituitary somatotroph pool, can respond because there are functioning somatotrophs for the analog to stimulate. Patient 2, whose somatotroph population has been destroyed by radiation, has no functional cells for the analog to act on, so a GHRH analog will be ineffective; that patient requires direct GH replacement (somatropin) instead.
Option A: Option A is incorrect because GHRH analogs do not replace circulating GH directly; they depend on an intact somatotroph pool, so they are not equally effective regardless of pituitary status.
Option B: Option B is incorrect because it reverses the expected outcome: the analog works in the patient with intact somatotrophs (Patient 1), not the one whose somatotrophs were destroyed (Patient 2); radiation destroys rather than sensitizes the target cells.
Option C: Option C is incorrect because GHRH analogs can stimulate GH release when functioning somatotrophs are present, so they do not fail under all circumstances.
Option D: Option D is incorrect because adding a somatostatin receptor analog (which suppresses GH) would oppose the goal of stimulating GH release and is not required; the determinant of efficacy is somatotroph integrity, not co-administration of an SSA.
6. A patient with hypopituitarism on a stable, borderline hydrocortisone replacement dose is about to begin somatropin (recombinant GH (growth hormone)) replacement. Integrating somatropin's effect on drug-metabolizing enzymes with the pharmacokinetics of glucocorticoid replacement, what risk should the clinician anticipate, and why?
A) Somatropin inhibits CYP3A4 (cytochrome P450 3A4), raising hydrocortisone levels and risking iatrogenic Cushingoid effects that require a preemptive dose reduction
B) Somatropin induces CYP3A4 (cytochrome P450 3A4), accelerating clearance of hydrocortisone; in a patient already on a borderline replacement dose, the increased glucocorticoid clearance can lower effective cortisol exposure and precipitate adrenal insufficiency, so the hydrocortisone dose may need to be increased
C) Somatropin displaces cortisol from receptors in target tissues, producing glucocorticoid excess that necessitates withholding hydrocortisone entirely
D) Somatropin has no interaction with glucocorticoid metabolism; any symptoms after starting it reflect the natural course of hypopituitarism unrelated to drug interaction
E) Somatropin converts hydrocortisone into a more potent mineralocorticoid, causing hypertension and hypokalemia that require spironolactone rather than dose adjustment
ANSWER: B
Rationale:
This integrates somatropin's enzyme-inducing effect with glucocorticoid pharmacokinetics. Somatropin induces CYP3A4 (cytochrome P450 3A4), which accelerates the clearance of glucocorticoids such as hydrocortisone (and increases conversion of cortisol to inactive cortisone). In a patient whose adrenal axis is compromised (hypopituitarism) and who is maintained on a borderline replacement dose, this increased clearance can reduce effective cortisol exposure below requirement and unmask adrenal insufficiency, potentially precipitating adrenal crisis. The appropriate response is to ensure adequate glucocorticoid replacement before starting somatropin and to anticipate an upward adjustment (commonly on the order of 20 to 30%) afterward.
Option A: Option A is incorrect because somatropin induces rather than inhibits CYP3A4; it lowers, not raises, hydrocortisone exposure, so the risk is insufficiency, not Cushingoid excess.
Option C: Option C is incorrect because somatropin does not displace cortisol from receptors to cause glucocorticoid excess; the interaction is enzymatic (increased clearance), and withholding hydrocortisone would be dangerous.
Option D: Option D is incorrect because there is a well-defined CYP3A4-mediated interaction; attributing post-initiation symptoms solely to the natural course of disease ignores a clinically important and predictable drug interaction.
Option E: Option E is incorrect because somatropin does not convert hydrocortisone into a more potent mineralocorticoid; the mechanism is accelerated glucocorticoid clearance, and the correct management is glucocorticoid dose adjustment, not spironolactone.
7. Two women of similar age and weight receive identical somatropin (recombinant GH (growth hormone)) doses for GH deficiency. One takes oral estrogen; the other uses transdermal estradiol. The woman on oral estrogen has persistently low serum IGF-1 (insulin-like growth factor-1) and needs a higher somatropin dose. Integrating estrogen pharmacokinetics with hepatic IGF-1 production, which explanation is correct?
A) Oral estrogen undergoes first-pass portal delivery to the liver at high concentration, where it suppresses hepatic GH receptor signaling and reduces IGF-1 production for any given somatropin dose; transdermal estradiol bypasses portal first-pass exposure, so hepatic IGF-1 production is less suppressed and the same somatropin dose yields a higher IGF-1
B) Oral estrogen accelerates renal clearance of IGF-1, lowering serum levels, whereas transdermal estradiol does not affect IGF-1 clearance
C) Oral estrogen blocks subcutaneous absorption of somatropin at the injection site, reducing systemic somatropin exposure, while transdermal estradiol enhances somatropin absorption
D) Transdermal estradiol suppresses pituitary GH secretion more than oral estrogen, so the transdermal patient needs more somatropin, not less
E) Oral and transdermal estrogen have identical effects on IGF-1; the dose difference reflects random assay variation rather than a pharmacologic mechanism
ANSWER: A
Rationale:
This integrates the route-dependent pharmacokinetics of estrogen with hepatic IGF-1 physiology. Oral estrogen is absorbed into the portal circulation and reaches the liver at high first-pass concentration. Hepatic estrogen suppresses GH receptor signaling in hepatocytes, reducing IGF-1 production in response to a given somatropin dose. As a result, women on oral estrogen require higher somatropin doses to reach target IGF-1. Transdermal estradiol enters the systemic circulation directly, bypassing the portal first-pass effect, so hepatic estrogen exposure is much lower and IGF-1 production is not significantly suppressed — the same somatropin dose yields a higher IGF-1.
Option B: Option B is incorrect because the mechanism is suppression of hepatic IGF-1 production, not accelerated renal IGF-1 clearance.
Option C: Option C is incorrect because oral estrogen does not block subcutaneous somatropin absorption; the interaction occurs at hepatic IGF-1 generation, not at the injection site.
Option D: Option D is incorrect because it inverts the relationship: the oral-estrogen patient (not the transdermal one) needs more somatropin, and the effect is on hepatic IGF-1 production rather than pituitary GH suppression.
Option E: Option E is incorrect because oral and transdermal estrogen do not have identical effects on IGF-1; the route-dependent first-pass difference is a real, well-documented pharmacologic mechanism, not assay noise.
8. A patient with acromegaly is being switched from three-times-daily subcutaneous (SC) octreotide to octreotide LAR (long-acting release). The clinician must decide how to manage the transition so that GH (growth hormone) suppression is not lost. Integrating the pharmacokinetics of the depot microsphere formulation with the goal of continuous disease control, what is the correct approach?
A) Discontinue SC octreotide the day before the first octreotide LAR injection, because the depot reaches therapeutic levels within hours and overlapping the two would cause octreotide toxicity
B) Give the first octreotide LAR dose at double strength and stop SC octreotide immediately, because the loading microspheres release a rapid initial burst that covers the transition
C) Switch directly with no bridging and no dose change, because octreotide LAR achieves steady therapeutic concentrations immediately, identical to lanreotide Autogel
D) Continue SC octreotide for approximately the first 14 days after the initial octreotide LAR injection, because the poly(lactic-co-glycolic acid) (PLGA) microspheres do not release octreotide at therapeutic concentrations until roughly 2 weeks; SC bridging maintains GH suppression during this lag
E) Replace octreotide entirely with oral octreotide tablets during the transition, since oral octreotide provides immediate coverage while the depot takes effect
ANSWER: D
Rationale:
This integrates the depot's release kinetics with the need for uninterrupted GH suppression. Octreotide LAR consists of poly(lactic-co-glycolic acid) (PLGA) microspheres that do not release octreotide at therapeutic plasma concentrations until approximately 14 days after the first injection. If short-acting SC octreotide were stopped at the moment of the first LAR injection, the patient would have roughly 2 weeks of subtherapeutic levels and loss of GH control. The correct approach is to continue SC octreotide as bridging therapy for about the first 14 days after the initial LAR dose, then discontinue it once the depot reaches therapeutic levels.
Option A: Option A is incorrect because octreotide LAR does not reach therapeutic levels within hours; stopping SC octreotide before the depot is active would leave a 2-week gap in GH suppression, and overlap during the lag is intended rather than toxic.
Option B: Option B is incorrect because octreotide LAR microspheres do not produce a rapid initial therapeutic burst; the standard starting dose is used without doubling, and bridging is still required.
Option C: Option C is incorrect because octreotide LAR does not achieve immediate steady concentrations; that lag-free behavior describes lanreotide Autogel's gel depot, not octreotide LAR microspheres.
Option E: Option E is incorrect because oral octreotide is not the standard bridging strategy here; octreotide is a peptide subject to gastrointestinal degradation, and the established bridge is continued SC octreotide during the 14-day lag.
9. A patient undergoes a macimorelin stimulation test for suspected adult GH (growth hormone) deficiency while taking carbamazepine. The peak GH is low, seemingly confirming deficiency. Integrating macimorelin's metabolism with the interpretation of the test, what is the most appropriate conclusion?
A) The low GH peak definitively confirms GH deficiency, and macimorelin metabolism is irrelevant to test interpretation
B) The low GH peak indicates carbamazepine directly suppresses pituitary somatotrophs, so the diagnosis is secondary GH deficiency caused by the anticonvulsant
C) Carbamazepine is a strong CYP3A4 (cytochrome P450 3A4) inducer and macimorelin is a CYP3A4 substrate; induction accelerates macimorelin clearance and lowers its exposure, which can blunt the GH peak and produce a false-positive result, so the test should be repeated after discontinuing the inducer before diagnosing GH deficiency
D) Carbamazepine inhibits CYP3A4, raising macimorelin levels and producing a falsely elevated GH peak, so true deficiency is being masked
E) The result is invalid because macimorelin must always be given intravenously, and oral administration with any comedication produces unreliable peaks
ANSWER: C
Rationale:
This integrates the drug interaction with diagnostic interpretation. Macimorelin is a CYP3A4 (cytochrome P450 3A4) substrate. Carbamazepine is a strong CYP3A4 inducer; it accelerates macimorelin metabolism and reduces macimorelin plasma exposure. Lower exposure provides a weaker secretagogue stimulus at the ghrelin receptor, which can blunt the GH peak even when the patient's somatotroph function is actually intact — producing a false-positive diagnosis of GH deficiency. The correct conclusion is to recognize the interaction, discontinue the strong CYP3A4 inducer, and repeat the test before committing to a diagnosis.
Option A: Option A is incorrect because macimorelin metabolism is highly relevant; a CYP3A4 inducer can invalidate the low peak, so the result is not definitive.
Option B: Option B is incorrect because the blunted peak reflects reduced macimorelin exposure from accelerated metabolism, not direct carbamazepine suppression of somatotrophs.
Option D: Option D is incorrect because carbamazepine induces rather than inhibits CYP3A4; it lowers macimorelin exposure and blunts (not falsely elevates) the GH peak.
Option E: Option E is incorrect because macimorelin is an oral agent by design; the problem is the specific CYP3A4 induction interaction, not the oral route itself.
10. A diabetic patient with acromegaly is started on a first-generation somatostatin receptor analog (SSA). The endocrinologist warns that the effect on glycemic control cannot be predicted in advance and that close glucose monitoring is required early in therapy. Integrating the effects of SSAs on pancreatic islet hormones, which explanation best accounts for this unpredictability?
A) SSAs raise insulin secretion and lower glucagon secretion equally, so glucose always falls, and monitoring is needed only to detect hypoglycemia
B) SSAs suppress both insulin and glucagon secretion; because insulin lowers glucose and glucagon raises it, the net glycemic effect depends on which suppression dominates in a given patient, making the direction of change unpredictable and requiring early glucose monitoring
C) SSAs have no effect on islet hormones; glucose variability after starting an SSA is purely coincidental and unrelated to the drug
D) SSAs selectively destroy pancreatic alpha cells, guaranteeing severe hyperglycemia in every patient, so monitoring is used to titrate insulin upward
E) SSAs increase incretin secretion, reliably improving glucose tolerance, so the warning about unpredictability is unwarranted
ANSWER: B
Rationale:
This integrates the opposing actions of SSAs on islet hormones. Somatostatin receptor analogs suppress secretion of both insulin and glucagon from pancreatic islets. Because insulin lowers blood glucose and glucagon raises it, suppressing both produces opposing influences on glycemia; the net effect in any individual patient depends on which suppression predominates. As a result, the direction of glucose change is not predictable in advance, and glucose should be monitored closely in the early weeks of SSA initiation or dose escalation, particularly in a patient with diabetes.
Option A: Option A is incorrect because SSAs suppress insulin (they do not raise it), so glucose does not always fall; the premise is wrong.
Option C: Option C is incorrect because SSAs do have well-defined effects on islet hormones; the glycemic variability is drug-related, not coincidental.
Option D: Option D is incorrect because SSAs functionally suppress islet hormone secretion rather than destroying alpha cells, and the glycemic effect is not uniformly severe hyperglycemia in every patient.
Option E: Option E is incorrect because first-generation SSAs do not reliably increase incretin secretion or improve glucose tolerance; the unpredictable, bidirectional islet effect is exactly why monitoring is warranted.
11. A patient with acromegaly has mildly elevated liver enzymes at baseline, attributed to GH (growth hormone) excess-related hepatic steatosis. Pegvisomant is started, and over time IGF-1 (insulin-like growth factor-1) normalizes. The clinician must interpret subsequent liver enzyme trends, integrating pegvisomant's hepatotoxicity risk with the hepatic effects of the underlying disease. Which statement reflects the correct integrated reasoning?
A) Uncontrolled acromegaly itself can produce hepatic steatosis with mild enzyme elevation, and effective pegvisomant therapy that normalizes IGF-1 often improves those baseline elevations; however, pegvisomant can independently cause hepatotoxicity, so a new or rising transaminase elevation during therapy must be evaluated as a possible drug effect rather than assumed to be residual steatosis, with discontinuation if transaminases exceed five times the upper limit of normal
B) Any liver enzyme elevation during pegvisomant therapy is always due to residual acromegaly-related steatosis and never to the drug, so enzymes can be ignored once IGF-1 normalizes
C) Pegvisomant cannot affect the liver because it acts only at peripheral GH receptors outside hepatic tissue, so liver monitoring is unnecessary
D) Normalizing IGF-1 with pegvisomant always worsens hepatic steatosis, so rising enzymes confirm treatment success and warrant dose escalation
E) Liver enzyme monitoring is irrelevant for pegvisomant; the only monitoring parameter that matters is serum GH, which should be kept above the normal range
ANSWER: A
Rationale:
This integrates the disease's hepatic effects with the drug's hepatotoxicity risk. Uncontrolled acromegaly promotes hepatic steatosis, which can produce mild baseline transaminase elevations; when pegvisomant normalizes IGF-1, those disease-related elevations often improve. At the same time, pegvisomant can independently cause hepatotoxicity (clinically significant ALT (alanine aminotransferase)/AST (aspartate aminotransferase) elevations in roughly 5 to 8% of patients). The correct integrated reasoning is therefore to monitor liver function and to treat a new or rising transaminase elevation as a possible drug effect requiring evaluation — not to assume it is residual steatosis — with drug discontinuation if transaminases exceed five times the upper limit of normal.
Option B: Option B is incorrect because attributing all elevations to residual steatosis ignores pegvisomant's genuine hepatotoxicity risk and could miss drug-induced liver injury.
Option C: Option C is incorrect because pegvisomant does act at hepatic GH receptors (the liver is a principal target where it blocks IGF-1 generation) and can cause hepatotoxicity, so liver monitoring is required.
Option D: Option D is incorrect because normalizing IGF-1 tends to improve, not worsen, acromegaly-related steatosis, and rising enzymes are a safety signal rather than a marker of success justifying dose escalation.
Option E: Option E is incorrect because liver enzyme monitoring is essential for pegvisomant, and serum GH is not a useful monitoring parameter for this drug (GH rises during therapy); IGF-1, not GH, guides efficacy.
12. A patient with acromegaly has residual tumor and inadequate IGF-1 (insulin-like growth factor-1) control on a maximally dosed somatostatin receptor analog (SSA). The endocrinologist adds pegvisomant rather than substituting it. Integrating the complementary mechanisms of the two agents, what is the rationale for combination therapy rather than switching to pegvisomant alone?
A) Combining the two agents is purely to reduce the cost of therapy, since two partial doses are cheaper than one full dose, with no pharmacologic rationale
B) Pegvisomant and the SSA act at the same pituitary receptor, so combining them produces simple additive receptor occupancy and nothing more
C) The SSA acts at the pituitary somatotroph and can restrain tumor growth and GH (growth hormone) secretion, while pegvisomant blocks the GH receptor peripherally to drive IGF-1 into the normal range; combining them achieves superior biochemical (IGF-1) control while retaining the SSA's restraint on the pituitary tumor, which pegvisomant alone does not provide
D) Pegvisomant shrinks the tumor and the SSA normalizes IGF-1, so the combination is used because each agent covers the deficiency of the other in the opposite direction from their true effects
E) The combination is used because pegvisomant stimulates the GH axis and the SSA suppresses it, so the two cancel out and stabilize the patient at baseline
ANSWER: C
Rationale:
This integrates the complementary sites of action. The somatostatin receptor analog (SSA) acts at the pituitary somatotroph, suppressing GH secretion and offering restraint on tumor growth (SSAs can shrink or stabilize tumor). Pegvisomant acts peripherally at the GH receptor to block IGF-1 generation and is highly effective at normalizing IGF-1. Adding pegvisomant to a maximally dosed SSA — rather than switching — achieves superior biochemical control of IGF-1 while retaining the SSA's restraining effect on the pituitary tumor, which pegvisomant monotherapy does not provide (pegvisomant has no tumor-volume effect). The combination thus pairs central tumor restraint with peripheral IGF-1 normalization.
Option A: Option A is incorrect because the rationale is pharmacologic (complementary mechanisms), not merely cost; combination therapy is generally more, not less, expensive.
Option B: Option B is incorrect because the two agents do not act at the same pituitary receptor — the SSA acts at pituitary somatostatin receptors and pegvisomant at peripheral GH receptors — so the benefit is complementary, not simple same-receptor additivity.
Option D: Option D is incorrect because it inverts the true effects: pegvisomant does not shrink tumor and the SSA is not the primary IGF-1 normalizer in refractory disease; the combination works because each contributes its actual effect (SSA = tumor restraint/GH suppression; pegvisomant = IGF-1 normalization).
Option E: Option E is incorrect because pegvisomant does not stimulate the GH axis; it antagonizes the GH receptor peripherally, so the agents do not simply cancel each other out.
13. A patient who has taken somatropin (recombinant GH (growth hormone)) replacement uneventfully for years for adult GH deficiency is admitted to the intensive care unit with septic shock and multi-organ dysfunction. The ICU team asks whether the long-standing, well-tolerated somatropin should simply be continued. Applying the contraindication principle to this novel acute situation, what is the correct action and rationale?
A) Continue somatropin unchanged, because a drug tolerated for years cannot pose new risk during an acute illness
B) Increase the somatropin dose, because critical illness raises GH requirements and the anabolic effect will speed recovery
C) Continue somatropin but add an SSA (somatostatin receptor analog) to balance its effects during the acute illness
D) Continue somatropin because the contraindication applies only to patients newly starting the drug, not to those already established on therapy
E) Discontinue somatropin during the acute critical illness, because acute critical illness is a contraindication to somatropin regardless of prior tolerance — pharmacological GH exposure increased mortality in critically ill patients in pivotal trials — and restart it after recovery
ANSWER: E
Rationale:
This applies a known contraindication principle to a new clinical situation. Acute critical illness is a contraindication to somatropin, independent of how well the patient tolerated the drug previously, because pivotal controlled trials showed increased mortality when critically ill adults received GH. The principle is tied to the patient's current physiologic state (acute critical illness), not to their prior treatment history, so a patient established on replacement who becomes critically ill should have somatropin discontinued during the acute illness and restarted after recovery.
Option A: Option A is incorrect because prior tolerance does not exempt a patient from a state-dependent contraindication; the risk is conferred by the acute critical illness, not by drug novelty.
Option B: Option B is incorrect because increasing the dose is exactly the wrong action; pharmacological GH exposure in critical illness increased mortality, so escalation is hazardous.
Option C: Option C is incorrect because adding an SSA is not the management; the appropriate action is discontinuation of somatropin during the critical illness, not co-administration of another GH-axis drug.
Option D: Option D is incorrect because the contraindication is not limited to new starts; it applies to any patient in the state of acute critical illness, including those already established on replacement.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.